



APSA-ASCEPT

JOINT SCIENTIFIC MEETING
5-8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE

Poster program



Optimising medicines for optimal patient outcomes



www.apsa-ascept2017.com

#APSAASCEPT

Download the meeting app
Event code: apsa-ascept



Drug Discovery

417	New drug formulation for combating antibiotic resistance Hien Duong, The University of Sydney
418	Angiotensin II receptor type 1 transactivation of EGFR via TRIO-dependent mechanisms Liz Johnstone, University of Western Australia
419	Smad2 linker region: A central integrating point for GPCR mediated transactivation of tyrosine and serine/ threonine kinase receptors Danielle Kamato, The University of Queensland
420	Reversal of age related pseudocapillarization using direct actin & lipid raft disruptor drugs on in vitro liver sinusoidal endothelial cells Glen Lockwood, Centre for Education and Research on Ageing
421	The rational design of self-adjuvanting subunit vaccines by site-specific conjugation of protein antigens with Toll like receptor ligands Zhenghui Xu, The University of Queensland
422	The novel fatty acid epoxide analogue CTU targets the mitochondrion and depletes cardiolipin to promote killing of MDA-MB-231 breast cancer cells Hassan Choucair, The University of Sydney
423	Anti-proliferative activity of novel ω-3 epoxy fatty acid analogues in MDA-MB-231 triple negative human breast cancer cells Yassir Al-Zubaidi, The University of Sydney
424	Assessment of taste 1 receptor allosteric ligands for activity at metabotropic glutamate receptors Amy NY Chen, Monash University
425	Small molecule inhibitors of Amyloid β and α Synuclein (αSA53T) protein aggregation Sukanya Das, The University of Adelaide
426	Bias in fluorescence-based voltage-gated sodium channel assays Jennifer Deuis, The University of Queensland
427	Nrf2 activators in medicinal plants of the Australian Aboriginal Dharawal people Karthik Dhananjayan, Western Sydney University
428	Phosphatase and tensin homolog (PTEN) silencing suppresses Ca²⁺ responses in MDA-MB-231 breast cancer cells Trinh Hua, The University of Queensland
429	Comparison of analgesic and constipation profile of two G-protein biased endomorphin-2 analogue after intracerebroventricular administration in rats Mohammad Zafar Imam, The University of Queensland
430	Structure-based virtual screening for the rapid discovery of selective butyrylcholinesterase inhibitors Jared Miles, The University of Queensland
431	Natural product honokiol reduces Aβ42-induced toxicity in Caenorhabditis elegans, Aβ42 fibrillation, cholinesterase activity, DPPH radicals, and chelates iron(II) Jared Miles, The University of Queensland
432	Development and optimisation of a FLIPR high-throughput cAMP assay to screen for Gai mediated GPCR modulators Michael Morgan, The University of Queensland
433	Development of a BRET based assay for AT1R-EGFR transactivation: evidence for functional heteromers Shannon O'Brien, The University of Queensland
434	Consequences of pharmacological inhibition of store-operated calcium entry on calcium signalling in MDA-MB-468 breast cancer cells Greta Poo, The University of Queensland
435	The sweet taste receptor: A novel target for drug discovery? Susan Tan, University of New South Wales
436	Assessment of calcium responses induced by the transient receptor potential cation channel subfamily V member 4 (TRPV4) activator GSK1016790A in MDA-MB-468 breast cancer cells using automated epifluorescence microscopy Zara Wagner, The University of Queensland
437	PAR1 and PAR2 open TRPV4 with conserved signalling pathways Owen Woodman, RMIT University
438	Neuronal calcium sensor-1 (NCS-1) in the regulation of calcium homeostasis and cell death in MDA-MB-231 basal breast cancer cells Alice Bong, The University of Queensland
439	Understanding the physiological role of endogenous allosteric modulators in the muscarinic acetylcholine receptors Ee Von Moo, Monash University

Cardiovascular

457	Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: Results from the Tasmanian Atrial Fibrillation (TAF) study Endalkahcew Admassie Alamneh, University of Tasmania
458	Epicatechin's cardiovascular protective effects are mediated via opioid receptors and nitric oxide Andrew Fenning, Central Queensland University
459	Exploiting E3-ubiquitin ligase mediated protein degradation pathways as new therapeutic target strategies for cardiovascular disease and beyond Ingrid Gelissen, The University of Sydney

460	Nattokinase: A promising alternative in prevention and treatment of cardiovascular diseases Yiguang Lin, University of Technology Sydney
461	Gaps in anticoagulation knowledge in patients with atrial fibrillation Kehinde Obamiro, University of Tasmania
462	Phosphoinositide 3-kinase p110alpha gene delivery limits cardiac remodelling and inflammation in a pre-clinical model of type 2 diabetes Darnel Prakoso, Baker Heart and Diabetes Institute
463	Targeting Annexin-A1 to treat diabetic cardiomyopathy Jesse Walsh, Baker Heart and Diabetes Institute
464	β-Ile5-Angiotensin II as a novel treatment for cardiac fibrosis Yan Wang, Monash University
465	Functional regulation of bitter taste receptors (T2Rs) by B2-adrenergic and M2 muscarinic acetylcholine receptor Jilai Zhao, The University of Queensland
466	Gene therapy targeting the hexosamine biosynthesis pathway (HBP) attenuates markers of diabetic cardiomyopathy in a mouse model of type-2 diabetes (T2D) Charles Cohen, Monash University
467	Blood pressure lowering post-stroke; a review of the evidence supporting recommendations of draft Clinical Guidelines for Stroke Management 2017 Fahmida Ilyas, SA Health
468	Resveratrol shows neuronal and vascular-protective effects in older, obese, streptozotocin-induced diabetic rats Jordon Irwin, Central Queensland University
469	The microRNA miR-124 inhibits vascular smooth muscle cell proliferation by targeting S100 calcium-binding protein A4 (S100A4) Hyun Kook, Chonnam National University Medical School
470	The role of phospholipase A2 in the cardiovascular effects of Pseudechis australis snake venom Amna Mazeah, The University of Melbourne
471	Endotoxin tolerance-like response in human abdominal aortic aneurysm (AAA) macrophages Lara Meital, University of The Sunshine Coast
472	β3-adrenergic receptors in the rat cremaster muscle artery Samantha Saunders, University of New South Wales
473	The association between short sleep duration and BMI in Australian Indigenous children Joseph Tucci, La Trobe University
474	Vascular effects of Australian brownsnake venoms (<i>Pseudonaja spp.</i>): The role of secretory phospholipase A2 Nhi T Vuong, The University of Melbourne
475	Delineating the signal transduction pathways by which relaxin mediates its anti-fibrotic actions in human cardiac fibroblasts Chao Wang, Monash University
476	Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms Kaki Fan, Monash University
477	Comparing the anti-fibrotic effects of emerging treatments: Serelaxin and the IRAP inhibitor, HFI-419 to a clinically-used angiotensin receptor blocker and ACE inhibitor in a high salt-induced mouse model of kidney disease Matthew Shen, Monash University
478	Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Andrew Willis, Baker Heart and Diabetes Institute
479	Role of TRPC3 in endothelium-dependent vasodilation of rat mesenteric arteries Sarah Wright, University of New South Wales
480	An investigation of the vascular effects of Sailuotong, a standardised Chinese herbal formula, for vascular dementia Seungyeon Yeon, Western Sydney University / The Science of Integrative Medicine (NICM)

Clinical Pharmacology

491	Therapeutic drug monitoring of voriconazole Kanka Chaudhri, University of New South Wales / St Vincent's Hospital
492	Antithrombotic drug-drug interaction alerts in MedChart Amanda Crawford, University of Otago
493	Prescribing based on the effective dose 50 (ED50) Simon Dimmitt, University of Western Australia
494	'Mrs Have-A-Chat': Pilot study showing that following up an "AdherenceCheck" every two weeks for 9 months improves the management of medicines in the older-aged living in a rental retirement village Sheila Doggrell, Queensland University of Technology
495	Making adverse drug reactions visible Matthew Doogue, University of Otago
496	Severe cutaneous adverse reactions and the (in)accuracy of medicines information sources Marie-Claire Morahan, Canterbury District Health Board
497	Peri-operative medication dosing in obese elective surgical patients: A systematic review of clinical studies Zahid Hussain, University of Tasmania

498	Audit of individual patient use applications for high cost medicines at a tertiary hospital Joshua Inglis, Royal Adelaide Hospital
499	Cannabinoid toxicity post human intraperitoneal injection Catherine Lucas, University of Newcastle
500	Clinical relevance of drug-drug interaction alerts Sylvain Meslin, University of New South Wales / St Vincent's Hospital
501	A chiral UHPLC-MS/MS method to investigate the pharmacokinetics of enantiomeric ketorolac in human plasma Suzanne Parker, The University of Queensland
501.1	A suite of LC-MSMS assays to investigate the pharmacokinetics of meropenem in critically ill patients receiving renal replacement therapy Suzanne Parker, The University of Queensland
502	Current antimicrobial stewardship (AMS) practices in the Australian community pharmacies Tasneem Rizvi, University of Tasmania
503	Inappropriate drug prescribing in elderly hospitalised patients with falls and fractures Natalia Soerjadi, The Canberra Hospital
504	A time and motion study of phlebotomists' work Sophie Stocker, St Vincent's Hospital
505	Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials Janani Thillainadesan, Royal North Shore Hospital
506	A multicentre open-label pharmacokinetic-pharmacodynamic study of febuxostat in patients with chronic gout Bishoy Kamel, University of New South Wales / St Vincent's Hospital
507	A stimulation study to assess the possible contribution of measurement error in quetiapine depression trials Jia Ning Careen Tan, The University of Queensland
508	The perceived impact of medicines, foods and substances taken by mother on their breastfed baby Hilai Ahmadzai, Curtin University
509	The effect of deprescribing after chronic polypharmacy on locomotor activity and cognition in a preclinical model Swathi Ekambareshwar, The University of Sydney
510	A simple, sensitive and rapid LC-MS/MS method for the simultaneous measurement of anthracyclines, cyclophosphamide and taxanes in breast cancer patient samples Peter Galettis, University of Newcastle
511	Relationship between plasma dolutegravir concentration and cause of anti- HIV therapy discontinuation Mari Kato, National Hospital Organization Nagoya Medical Center
512	Preclinical models to understand the risks of single and multiple concurrent medicines in old age John Mach, Kolling Institute/ The University of Sydney/ Royal North Shore Hospital
513	Prevalence and prediction of adverse drug reactions in older inpatients with hyperpolypharmacy Rayan Nahas, Royal North Shore Hospital
514	Pharmacometrics to address weaknesses in Australian medical countermeasure product development Thomas Polasek, d3 Medicine, A Certara Company
515	Intravesical mitomycin C enhances spontaneous phasic contractile activity in the murine bladder Eliza West, Bond University
516	The influence of perioperative opioids on cancer metastasis Nan Xie, The University of Queensland
517	Simultaneous determination of adalimumab and infliximab in human serum by liquid chromatography/tandem mass spectrometry Mei Zhang, University of Otago
518	Ibuprofen in Infants younger than 6 months: What is the efficacy and safety profile? Victoria Ziesenitz, University of Basel Children's Hospital
519	The safety and pharmacokinetics of metformin in heart failure Gina Chowdhury, University of New South Wales / St Vincent's Hospital Sydney
520	The safety of Metformin in Haemodiafiltration Felicity Smith, University of New South Wales / St Vincent's Hospital Sydney
521	Discharge summaries: An untapped resource for optimising Adverse Drug Reaction identification Frida Djukiadmodjo, Austin Health

Toxicology

555	Inhibition of human Cav3.2 channels by synthetic cannabinoid MDMB-CHMICA in vitro Chris Bladen, Macquarie University
556	Potential role of herb-herb interactions in hepatotoxicity Susan Britza, University of Adelaide
557	QSAR models define molecular initiating events for multiple AOPs Davy Guan, The University of Sydney
558	Functional evaluations of synephrine and octopamine - stimulants in pre-workout supplements Andy Koh, Bond University

Pharmaceutical Science

563	Chemical profile and anti-cancer potency of <i>Dendrobium</i> species from China and Australia I Gusti Md Gde Surya C. Trapika, The University of Sydney
564	Olfactory targeted mucoadhesive microparticles for enhanced brain uptake of phenytoin Sasi Bhushan Yarragudi, University of Otago
565	Synthesis and characterization of a smart inulin hydrogel system for colon targeted drug delivery Franklin Afinjuomo, University of South Australia
566	Induction of localised vasodilation and hyperpermeability using a novel nitric oxide donor nanoparticle Houman Alimoradi, University of Otago
567	Scarring in horses – is there a way to objectively quantify an equine scar? Selena Boyd, The University of Queensland
568	Prediction of skin permeation based on solute properties using machine learning and statistical tools Hanumanth Srikanth Cheruvu, The University of Queensland
569	Quality of levofloxacin tablets: In vitro dissolution testing and content evaluation Ensieh Izadi, University of Tasmania
570	Evaluation of PLGA nanoparticles (NPs) uptake using Caco-2 cell monolayers Danhui (Cathy) Li, University of Auckland
571	Human NAT1 regulates invasion of MDA-MB-231 breast cancer cells by modulating the expression of MMPs Pengcheng Li, The University of Queensland
572	Effect of N-acetyltransferase 1 on the sensitivity of chemotherapeutics in breast cancer Courtney Mcaleese, The University of Queensland
573	An investigation of sodium fusidate and recombinant cytochrome p450 enzymes inhibition in-vitro John Mishriky, RMIT University
574	Physiologically-based IVIVC compared with conventional IVIVC for predicting <i>in vivo</i> pharmacokinetics of crushed paracetamol mixed with thickened fluids for swallowing disorders Chandramouli Radhakrishnan, 4am Software
575	Release of somatostatin monomers from self-assembled hydrogels Uma Rai, RMIT University
576	L-arginine protects skeletal muscle against statin-induced myopathy Kimberly Ryan, Central Queensland University
577	Intrinsic dissolution study of aspirin Dorothy Saville, University of Otago
578	Effect of storage on release from enteric coated diclofenac tablets Dorothy Saville, University of Otago
579	Drug content and in vitro dissolution of ciprofloxacin tablets: Comparison and Evaluation Deepali Sharma, University of Tasmania
580	Removal of interstitial hyaluronan with recombinant human hyaluronidase (rHuPH20) influences the systemic and lymphatic uptake of a monoclonal antibody in rats Ian Styles, Monash University
581	Preparation of viable and metabolically active epidermal membrane Krishna Chaitanya Telaprolu, The University of Queensland
582	Arylamine N-acetyltransferase 1 regulates cancer cell survival via modulation of pyruvate dehydrogenase Lili Wang, The University of Queensland
583	Biomedical applications of water-soluble pillar[n]arenes Nial Wheate, The University of Sydney
584	Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery Preeti Yadav, Monash University

Pharmacoepidemiology

400	Trends in anticoagulant use among people with dementia in Australia Jenni Ilomaki, Monash University
401	Mapping medication burden, prescribing and dispensing patterns within community dwelling elderly clients of community pharmacies Lauren Corre, University of South Australia
402	Use of medicines with sedative or anticholinergic properties and medicine-induced deterioration in older people: An intermediary pathway to frailty Renly Lim, University of South Australia
404	Health professionals' and researchers' opinions on conducting clinical deprescribing trials Alexander Clough, The University of Sydney
405	Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mitchell Redston, The University of Sydney
406	Exercise and weight loss supplements: Understanding the risks Robin Bell, University of Newcastle
407	SGLT2 inhibitors and diabetic ketoacidosis - review of PI's and comparison with Endocrinology position statement Genevieve Gabb, SA Health
408	Health literacy and uptake of osteoporosis medications in a population-based sample of Australian women Sarah Hosking, Monash University
409	SGLT-2 inhibitors and diabetic ketoacidosis - review of CMI and comparison with Endocrinology position statement Fahmida Ilyas, SA Health
410	Evaluation of bortezomib use in Queensland public hospitals for the treatment of multiple myeloma Crystal Loke, The University of Queensland
411	What do women want to know about menopausal symptoms management: An Australian medicines call centre analysis Rifani Bhakti Natari, The University of Queensland
412	Patterns of oral anticoagulant use in people with and without dementia: A systematic review Taliesin Ryan-Atwood, Monash University
413	Consumer information gaps and concerns regarding opioid analgesics and anxiolytic/hypnotic/sedative medicines Kudrat Sidhu, The University of Queensland
414	The Medication Regimen Simplification Guide for Residential Aged Care (MRS GRACE): A novel tool to optimise medication regimens for residents of aged care facilities Esa Chen, Monash University
415	What are the predictors of persistent prescription opioid analgesic use for non-cancer pain in Australia? Samanta Lalic, Monash University
416	Anovulatory infertility in Australia: A retrospective analysis of medicine use and health outcomes Mohammed Altaf, The University of Queensland

Education

440	Experiences in defining Entrustable Professional Activities to drive the learning of undergraduate pharmacy students Hesham Al-Sallami, University of Otago
441	Older people as university-based instructors to improve empathy and attitudes toward older people among first-year pharmacy students Simon Bell, Monash University
442	A digital portfolio: Learning gains and efficiencies for placements in new BPharm programme Lynne Bye, University of Auckland
443	Education for vancomycin – what works? Jane Carland, University of New South Wales/St Vincent's Hospital Sydney
444	Creating a labelling standard for compounded medicines – a learning task requiring higher order thinking skills Stephen Carter, The University of Sydney
445	Nursing students are more reliant on ongoing assessment scores to succeed in pharmacology than paramedic or optometry students Sheila Doggrell, Queensland University of Technology
446	Do pharmacy students have different personal characteristics than other students? James Green, University of Otago
447	Student engagement in learning: Learning space matters James Blanchflower, The University of Sydney
448	Pilot study of a clinical pharmacology exam for medical students prior to hospital internship in Newcastle Catherine Lucas, University of Newcastle
449	Evaluation of a new integrated Master of Pharmacy curriculum Rebecca Roubin, The University of Sydney
450	Development of a program wide pharmaceutical compounding strategy using the scaffold learning approach to improve student learning outcomes Vijay Suppiah, University of South Australia
451	Gamification to enhance learning of difficult concept in Pharmacology Lisa BG Tee, Curtin University

452	Improving student engagement: Utilising a wet pain practical Waltraud (Trudie) Binder, University of New South Wales
453	Demonstrating the ability to prescribe medicines: A multi-professional view Lynda Cardiff, Queensland University of Technology
454	Does attending lectures matter when lecture recordings are available? Results for a preliminary study of nursing students in pharmacology Sheila Doggrell, Queensland University of Technology
455	Implementation of a consistent and structured approach to small class workshops: A case study in pharmacy education at Monash University Nilushi Karunaratne, Monash University
456	Practicing pharmacists' preferences for skills taught in an undergraduate pharmacy program Carlo Marra, University of Otago
456.1	Developing a new unit in a new curriculum Betty Exintaris, Monash University

Pharmacogenomics

481	Clinically actionable CYP450 pharmacogenotypes relevant to analgesics used for alleviating rheumatoid arthritis pain in community-dwelling older Australians Thilani Dias, University of Newcastle
482	Cytochrome interactions between lumacaftor and ivacaftor undergoing Orkambi cystic fibrosis therapy Elena Schneider, Monash University
483	The role of efflux transporters in the transfer of drugs from mother to breastfed infant via breastmilk Hilai Ahmadzai, Curtin University
484	Silencing ABC2 transporter gene enhances oxaliplatin chemo-sensitivity in colorectal cancer cells Riya Biswas, Auckland University of Technology
485	Raised urinary excretion of thymine following an oral load is a marker for severe fluoropyrimidine toxicity John Duley, The University of Queensland
486	The ethics of direct-to-consumer pharmacogenomic screening in primary care Suzanne Harvey, The University of Queensland
487	Therapeutic drug safety, important to 'Close the Gap' for Aboriginal and Torres Strait Islanders: An illustrative case of phenytoin hypersensitivity syndrome Fahmida Ilyas, SA Health
488	Physiologically based pharmacokinetic modelling of atomoxetine in the different CYP2D6 genotypes Seok-Yong Lee, Sungkyunkwan University
489	No significant effect of CYP3A, ABCB1, POR and NR112 polymorphisms on acute rejection and nephrotoxicity in the first 3 months post kidney transplantation in patients receiving tacrolimus Rong Hu, The University of Adelaide
490	ABCB1 pharmacogenetics in Papua New Guinea HIV/AIDS patients and association with efavirenz CNS/Psychiatric adverse effects Helena Van Schalkwyk, The University of Adelaide

Neuro- and Behavioural Pharmacology

522	GLP-1-induced anorectic and emetic responses are mediated via exendin (9-39)-sensitive mechanisms in Suncus murinus Sze Wa Chan, Caritas Institute of Higher Education
523	Polyphenol reversal of amyloid-induced neurite dysfunction Mirabel Alonge, University of Adelaide
524	Endosomal trafficking kinetics of orexin receptors as measured by BRET trafficking assay Natasha Dale, Harry Perkins Institute of Medical Research
525	Splicing regulation and function of cytosolic sulfotransferase: SULT4A1 Misgana Idris, The University of Queensland
526	Diverse approaches to understand functional pharmacology- examples of the serotonin 5-HT1B and 5-HT2A receptors Amber Ko, Eurofins Pharma Discovery Services
527	Statins exhibit diverse effects on behaviour and brain cytokine levels in an in vivo model of LPS-induced neuroinflammation Amelia McFarland, Griffith University
528	The role of caveolae in glioblastoma invasiveness Wenjun Pu, The University of Queensland
529	Air on a G-String: Guanine as a biological stress sensor in relation to depression and neurological disorders Tim Shaw, The Peter Doherty Institute
530	Behavioural, pharmacologic and histologic characterisation of a rat model of mechanical low back pain Thomas Park, The University of Queensland
531	Morphine dosing affects development of antinociceptive tolerance and motor behaviour Alok Kumar Paul, University of Tasmania

Drug Disposition and Response

532	Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma Hannah Yejin Kim, The University of Sydney
533	Optimisation of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable <i>Pseudomonas aeruginosa</i> via the hollow-fibre infection model and mechanism-based modelling Rajbharan Yadav, Monash University
534	Evaluation of optimised piperacillin plus tobramycin combination dosage regimens against <i>Pseudomonas aeruginosa</i> (Pa) for patients with altered pharmacokinetics via the hollow fibre infection model and mechanism-based modelling Rajbharan Yadav, Monash University
535	High-throughput assay for simultaneous quantification of the plasma concentrations of Omeprazole, Dextromethorphan, Midazolam, Losartan and their metabolites using liquid chromatography/tandem mass spectrometry (LC-MS/MS) Santosh KS Adiraju, The University of Queensland
536	The influence of sampling time on estimated tobramycin exposure in cystic fibrosis patients Yanhua Gao, The University of Queensland
537	Tumour expression of copper transporters in colorectal cancer patients Johnson Liu, University of New South Wales
538	Investigating the optimal initial dose of gentamicin in paediatric oncology patients considering efficacy and reduction in renal function Carolina Llanos, The University of Queensland
539	Interaction of mangosteen extract and alpha mangostin with metformin in diabetic rats: PK/PD studies Lucy Sasongko, Institut Teknologi Bandung
540	Early prediction of chemotherapy efficacy in liver cancer cells by specific ROS levels Haotian Yang, The University of Queensland
541	Drug delivery to the intestinal lymphatics enhances the immunosuppressant effects of mycophenolic acid in mice Ruby Panakkal Kochappan, Monash University
542	Polymer precipitation inhibitors can maintain drug supersaturation and increase in vivo absorption from lipid-based formulations Estelle Suys, Monash University

Urogenital and Gastrointestinal

543	The effects of aging on polarization in collagen sandwich-cultured hepatocytes Sun Woo Kang, Anzac Research Institute
544	Tachykinin NK2 receptor expression in the human colon; an insight into the influence of gender, age and disease Stelina Drimousis, University of New South Wales
545	Antibiotic guidelines for Urinary Tract Infections (UTI) and hospital length of stay Poh Loh, Royal Perth Hospital
546	Age-related variations in porcine bladder responses to clinical antimuscarinics Christian Moro, Bond University
547	Histamine receptors as regulators of urothelial and detrusor contractile activity Christian Moro, Bond University
548	β-adrenoceptors in the urinary bladder vasculature Donna Sellers, Bond University
549	Ethanol as an intravesical vehicle: Effects on bladder function Katrina Smith, Bond University
550	Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel Briohny Spencer, Griffith University
551	Purinergic P2X7 receptor antagonist A804598 reduces the damage induced by acrolein in ex-vivo porcine bladders Zhinoos Taidi, University of New South Wales
552	Histamine receptor (Hrh) subtypes mediate bladder afferent sensitivity in mice Ashlee Caldwell, University of Adelaide
553	Characterization of Nav channels in colon-innervating dorsal root ganglion neurons in mice Andelain Erickson, The University of Adelaide
554	Pharmacological effects of a jungle ginger on rat prostatic smooth muscle Nguok Ngie Eunice Su, Monash University

Inflammation/respiratory

559	The immunomodulation of dynorphin 3-14 on lipopolysaccharide-activated toll-like receptor 4 signalling pathway Peter Cabot, The University of Queensland
560	Intranasal delivery of the TLR7 agonist, imiquimod, protects against influenza A virus-induced morbidity in mice Jonathan Erlich, RMIT University
561	IRAK3 modulates NFκB through its guanylate cyclase activity Lubna Freihat, Monash University
562	Pharmacological characterisation of small molecule C5aR1 inhibitors in primary human macrophages Xaria Li, The University of Queensland

Pharmacy Practice

585	Drug use evaluation of levetiracetam at a tertiary teaching hospital Oksana Burford, Curtin University
586	Hospital pharmacists' and patients' views about what constitutes effective pharmacist-patient communication Bernadette Chevalier, The University of Queensland
587	Improving community pharmacy management of non-prescription medicine requests with mystery shopping and feedback Jack Collins, The University of Sydney
588	Surgical antibiotic prophylaxis use and infection prevalence in breast surgery procedures in a major teaching hospital in Western Australia Petra Czarniak, Curtin University
589	Psychometric testing of scales measuring perinatal depression literacy and comfort with providing perinatal depression care Sarira El-Den, The University of Sydney
590	Communication between community pharmacies and prescribers in New Zealand James Green, University of Otago
591	Medicine use in early childhood: Which vaccines, branded or generic medicines do parents of children five and under choose? James Green, University of Otago
592	What is the attitude of Australian pharmacists to the use of medicines for assisted dying at end-of life? Tony Hall, Queensland University of Technology
593	Health professionals' opinion of a brief email format for answering medicine information enquiries Ann Roslyn Hutton, Christchurch Hospital
594	Pharmacy and the ethical dilemma of Physician Assisted Suicide (PAS): A systematic review Sami Isaac, The University of Sydney
595	Common co-morbidities and polypharmacy in elderly patients in a South Australian tertiary healthcare hospital Muhammad Khan, The University of Queensland
596	Weight loss product usage and advice in community pharmacies in North Queensland Gillian Knott, James Cook University
597	Factors associated with pharmacists' perceptions of working conditions in Canada Carlo Marra, University of Otago
598	What Is Polypharmacy Exactly (WIPE) Nashwa Masnoon, University of South Australia, Royal Adelaide Hospital
599	Do Australian pharmacists feel prepared to respond to local disasters and emergencies? Elizabeth McCourt, Queensland University of Technology
600	Over-the-counter medicines: The complexity of decision-making for pharmacy students Sara McMillan, Griffith University
601	Insights into consumer use, storage and disposal of unwanted and expired medicines Fiona Kelly, Griffith University
602	Non-prescription sales of antimicrobials in developing countries: A systematic review Fatima Sakeena, The University of Sydney
603	Principlism: An approach for determining ethical responsibilities of pharmacists when selling complementary medicines Amber Salman Popattia, The University of Queensland
604	Implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS) Mouna Sawan, The University of Sydney
605	Pharmacist perceptions of psychotropic monitoring in Australian aged care facilities Carl Schneider, The University of Sydney
606	Do pharmacists fit in the disaster health management team puzzle? Judith Singleton, Queensland University of Technology
607	How do health professionals perceive medicinal cannabis? Results of a systematic review Judith Singleton, Queensland University of Technology
608	Community pharmacists' perception of their role in primary mental health care Mary Wong, University of Otago
609	Electronic prescribing of insulin with Medications Management, Anaesthetics & Research Support (MARS) Hua Bing Yong, Princess Alexandra Hospital
610	Prevalence of potentially inappropriate medicine use in older Australians living in residential aged care facilities Hosam Bony, University of South Australia
611	Comparison of the management of medicines in the older-aged living in different leasehold retirement villages Sheila Doggrell, Queensland University of Technology
612	Tablet crushers: The investigation of powder loss using different sizes and brands of atorvastatin tablets Mitchell Evelyn, The University of Queensland
613	Study of the 'Hospital Formularies' of different level hospitals based on the 'WHO - Essential Medicines List' Bharatkumar Gajjar, Pramukhswami Medical College
614	How does perceived cost influence pharmacy patronage? A scoping review. Bethany Grew, The University of Sydney
615	Improving outcomes in type 2 diabetes patients using a pharmacist diabetes intervention tool Laetitia Hattingh, Griffith University
616	Complementary and alternative medicine (CAM) use in cancer patients commencing new chemotherapy Karly Huber, Griffith University

617	Are pharmacists' estimates of medication adherence related to HbA1c levels in people with type 2 diabetes? Mangesh Kharjul, Otago University
618	Developing a screening tool to identify people with swallowing difficulties of solid oral medicines Esther Lau, Queensland University of Technology
619	Dose administration aids - how useful do patients think they are? Esther Lau, Queensland University of Technology
620	Factors influencing non-adherence among people living with chronic health conditions in Australia Amary Mey, Griffith University
621	Medication information and supply behaviours in elite athletes Lily Ngu, University of Western Australia
622	Healthcare and pharmacy service provision for Pakistani migrants residing in developed countries: A systematic review Ahsan Saleem, The University of Queensland
623	Piloting a novel observational technique for the administration of medicines to children in paediatric wards Jose Manuel Serrano Santos, Queensland University of Technology
624	Evaluation of antimicrobial use in a tertiary care hospital by using specific indicators: A prospective, observational study Siavash Shahbazi Nia, Al-ameen College of Pharmacy
625	Does medication increase the risk of infection burden in residential aged care? Mohammad Shohel, Curtin University
626	Measuring menopause symptoms: A scoping review of existing tools Joy Spark, University of New England
627	Completeness of controlled drug prescribing in regional NSW Joy Spark, University of New England
628	Tablet crusher comparisons: Usability testing by people with and without limited hand function Kathryn Steadman, The University of Queensland
629	Management of non-healing mouth ulcer presentations in community pharmacies Brigitte Janse van Rensburg, The University of Queensland
630	Chronic disease, medications and lifestyle: Perceptions from a regional Victorian Indigenous Community Joseph Tucci, La Trobe University
631	Perceptions of credible drug information sources for Indigenous people attending a regional Aboriginal Health Service Joseph Tucci, La Trobe University